A fast-growing network of psychiatry clinics and research sites
Chief Executive Officer, Director, Co-Founder
Yaron Conforti is an entrepreneur and the principal of EmmCap Corp., an investor in venture-stage companies. EmmCap actively participates in its early-stage investments via board and management roles. Yaron has over 20 years of venture capital investing and operating experience, including founder and CEO roles in companies across different industries. Past EmmCap investments include Abacus Health Products (acquired by Charlotte’s Web), GR Silver Mining (TSXV:GRSL), IM Cannabis (NASDAQ:IMCC) and Enveric Biosciences (NASDAQ:ENVB). Yaron previously served in senior investment banking roles at Desjardins Securities and Sandfire Securities where he focused on micro/small cap equities.
Reid Robison, MD, MBA
Chief Medical Officer, Director
Dr. Reid Robison is a board-certified psychiatrist who was named Best Psychiatrist in Utah by Salt Lake City Weekly’s Best of Utah Body & Mind 2020. Dr. Robison is the co-founder of Cedar Psychiatry and serves as the Medical Director for the Center for Change, a leading Eating Disorder center. He was previously a coordinating investigator for the MAPS-sponsored MDMA-assisted psychotherapy study of eating disorders. As an early adopter and researcher of ketamine in psychiatry, Dr. Robison led a pivotal IV ketamine study for treatment-resistant depression by Janssen, leading up to the company’s recent FDA-approval of Spravato™. To date, Dr. Robison has guided thousands of ketamine therapy journeys and hundreds of Spravato™ dosing sessions. As a social entrepreneur, Dr. Robison has built a number of purpose-driven companies including Tute Genomics which was acquired by PierianDx in 2016. Dr. Robison is also an adjunct professor at both the University of Utah and Brigham Young University and is the founder of the Polizzi Free Clinic, a free mental health clinic for marginalized people based in Salt Lake City, Utah.
Paul Thielking, MD
Chief Scientific Officer
Dr. Paul Thielking is board certified in psychiatry, hospice & palliative medicine, and integrative medicine. Dr. Thielking is the principal investigator for a psilocybin enhanced group psychotherapy intervention for cancer patients with depression and a co-investigator on a study for ketamine-assisted psychotherapy for opioid use disorder. He has extensive experience with creating innovative group therapy interventions for patients with serious illness and has successfully integrated ketamine-assisted psychotherapy services within an academic outpatient oncology clinic for cancer patients with depression. Dr. Thielking was director of psycho-oncology at the University of Utah Huntsman Cancer Institute for five years and was previously an associate professor in the department of psychiatry at the university of Utah. He was also the medical director of the tobacco treatment program at the Huntsman Cancer Institute. He has extensive experience with medical students, residents and fellows. Dr. Thielking is a graduate of the California Institute of Integrative Studies’ Certification of Psychedelic Therapy and Research program.
Seneca Anderson began her career in business process redesign and engineering in higher education, including with New York University, Pepperdine University and the California State University system. In addition to analyzing business flow to identify process gaps and maximize efficiencies, Seneca met with stakeholders to unify and execute their vision. After seventeen years in higher education, she transitioned her skills to building best in class behavioral health clinics in the United States. She is most well-known for maximizing set-up and design, and negotiating with insurance companies to maximize clinic reimbursement, while offering timely outpatient mental health care, including TMS, Spravato™ and ketamine-assisted psychotherapy.
Prakash Gowd, MBA, BSc Pharm, C Dir
Chief Operating Officer
Prakash brings 25 years of experience in capital markets, biopharma and health sciences. He is Co-Founder and Advisor at Lobo Genetics, previously held senior healthcare equity research roles at CIBC, Canaccord Capital and National Bank Financial, was a consultant to life science companies, and helped guide new product planning and commercial development at GlaxoSmithKline. He also served as Audit Chair and board director of a public drug development company. Prakash holds an MBA from McGill University, a BSc Pharmacy from the University of British Columbia, and a Chartered Director designation.
VP, Corporate Development
Prior to Novamind, Nolan was an analyst at First Republic Capital, a Canadian investment bank, where he financed early-stage growth companies with debt and equity private placements. In 2017, he graduated from Dalhousie University where he majored in finance and earned a Bachelor of Commerce. Nolan has completed level II of the CFA program.
Board of directors
Jesse Kaplan, CFA
Jesse Kaplan has been a partner with Plaza Capital Limited since 2015. His career has focused on advising and investing in early stage growth companies. This has included extensive work helping companies through the process of going public in both Canada and the United States. Jesse was previously a senior analyst at Harborview Advisors LLC, a New York based investment firm and Palladium Capital Advisors, LLC, a NASD member investment bank. Currently, he is a board member of Abacus Health Products (CSE:ABCS) among other successful companies.
Sruli Weinreb, is a founder and managing partner at Plaza Capital, a boutique investment & advisory firm focused on early-stage growth companies. Sruli has co-founded, advised, financed, and continues to serve at many innovative companies across a spectrum of industries. He is currently a cofounder and Director at Novamind, CEO at Findev (TSVX: FDI) a real estate investment platform and CEO at Lake Central Air Services, the world’s leading integration partner for the airborne geophysical survey industry.
Chuck Rifici, CPA, MBA
Chuck is a pioneer of the North American cannabis industry, having created and managed opportunities which have had an incredible and widespread impact on the Canadian cannabis landscape. The founder of Canopy Growth (FKA Tweed Marijuana), Chuck is a chartered professional accountant (CPA). He obtained his MBA from Queen’s University and holds a BASc in Computer Engineering from the University of Ottawa.